Nicox is on track to file for approval of its NCX 470 therapy for eyesight-robbing disease glaucoma after it showed efficacy in a second pivotal trial. The positive data from the Phase 3 Denali trial ...
The US launch of a myopia control spectacle lens, research into modifiable myopia risk factors, and atropine developments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback